Funding for this research was provided by:
National Cancer Institute (R25 CA57726, K22 CA186979)
Received: 12 July 2017
Accepted: 23 March 2018
First Online: 19 April 2018
Ethics approval and consent to participate
: The University of North Carolina Institutional Review Board approved the trial protocol (IRB #14-1873). Immediately preceding the training session, research staff disseminated study fact sheets to participants. The IRB granted a waiver of written documentation of informed consent.
: Not applicable.
: N.T. Brewer has received research grants from Merck and Pfizer and has served on a paid advisory board for Merck. The remaining authors (TM, MH, CL, MG) declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.